Open

PD-1 blocker and gene therapy study for patients with Hodgkin Lymphoma

To estimate the objective response rate and progression free survival of anti-PD-1 therapy after progression on CD30 CAR-T cell therapy.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

You will be scheduled to receive standard of care anti-PD-1 therapy. You will be seen in clinic for visits that may include infusions, lab tests, imaging, or biopsies.

In-person visits:
1 year for treatment and initial follow-up, long term follow-up for 15 years

Phone or online visits:
Visits can be combined with regular clinical appointments

Total length of participation:
12 weeks of treatment and follow-up

Looking for Specific Volunteers

Able to participate:

Confirmed diagnosis of relapsed/refractory Hodgkin lymphoma after at least 3 lines of prior therapy with clinical progression after CAR-T therapy
You have previously been treated with anti-PD-1 therapy before your prior CAR-T therapy
Relapsed Hodgkin lymphoma
Your plan for treatment includes starting on anti-PD-1 therapy (Nivolumab, Pembrolizumab, etc)
Willing to provide blood samples

Not eligible if:

You have received anti-CD30 CAR-T within 6 weeks
Not considered an acceptable candidate for anti-PD-1 therapy, as decided by study doctor
Received chemotherapy or anti-PD-1 therapy following CD30 CAR-T (if Arm 1)

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

UNC Immunotherapy
UNCImmunotherapy@med.unc.edu

Visit Study Website

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Natalie Grover
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lymphoma)

IRB Number

19-1407

ClinicalTrials.gov

NCT04134325

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.